Assessment of The Pharmacoeconomic Efficiency of Medicines Used in The Treatment of Pneumonia

Pneumonia is one of the most common and clinically significant diseases of the respiratory system, requiring, especially in severe cases, inpatient treatment, multicomponent drug therapy, and substantial medical resources. The continuously expanding range of medicines, the introduction of modern antiviral and antibacterial drugs into clinical practice, as well as the widespread use of symptomatic and supportive treatment agents, demand efficient and rational use of the financial and material resources available in the healthcare system. From this standpoint, applying pharmacoeconomic approaches to the treatment of pneumonia makes it possible to comprehensively assess both the clinical significance of medicines and the funds spent on them. This article discusses the theoretical and practical aspects of using cost analysis, ABC analysis, VEN analysis, and the ABC/VEN matrix in the pharmacoeconomic evaluation of medicines used in the treatment of patients with pneumonia. In cost analysis, the total cost is calculated based on the unit price of a medicine and the quantity consumed. ABC analysis makes it possible to divide medicines into groups A, B, and C according to their share of total costs, while VEN analysis assesses their clinical significance as V — vital, E — essential, and N — non-essential agents. The ABC/VEN matrix, in turn, allows for an integrated assessment of economic and clinical indicators. The results of the analysis show that the bulk of medicine costs in the treatment of pneumonia falls on a limited number of drugs, and that some medicines may be highly costly while having low clinical significance. For this reason, pharmacoeconomic analysis is an important tool for shaping rational pharmacotherapy in pneumonia therapy, planning medicine procurement, and improving the budget efficiency of healthcare institutions.

Hali tarjima qilinmagan